603392.SS Stock Analysis
60
Uncovered
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and equipment, and vaccines. The company is headquartered in Beijing, Beijing and currently employs 3,103 full-time employees. The company went IPO on 2020-04-29. The firm produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The firm is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.